7 news items
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
24th Annual Employee Healthcare Conference in Las Vegas, NV on Tuesday, May 14, 2024, at 2:20 p.m. local time or 5:20 ET. Live webcasts
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
ATNM
AZN
BMY
18 Apr 24
. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
16 Apr 24
shares of its common stock to eight new employees, consisting of inducement stock options to purchase an aggregate of 16,480 shares of common stock
uhiaz8j800wu11bfbueyg6v91slhusg3681gd4j0qrd52ubmwcg33
RYTM
11 Mar 24
shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 9,180 shares of common stock
qv2jrmunn273nhy2tnbq roadzx
RYTM
6 Mar 24
setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel
- Prev
- 1
- Next